{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T16:40:20Z","timestamp":1730392820499,"version":"3.28.0"},"reference-count":12,"publisher":"Elsevier BV","issue":"6-7","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer\/Radioth\u00e9rapie"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.canrad.2024.07.004","type":"journal-article","created":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T12:13:23Z","timestamp":1727439203000},"page":"510-512","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Practice-changing trials on breast cancer"],"prefix":"10.1016","volume":"28","author":[{"given":"Youlia","family":"Kirova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jihane","family":"Bouziane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Loap","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.canrad.2024.07.004_bib0065","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.canrad.2024.07.004_bib0070","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1016\/S0140-6736(11)61629-2","article-title":"Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials","volume":"378","author":"Darby","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.canrad.2024.07.004_bib0075","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1016\/S0140-6736(14)60488-8","article-title":"Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials","volume":"383","author":"McGale","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.canrad.2024.07.004_bib0080","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/S0140-6736(08)60348-7","article-title":"The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial","volume":"371","author":"Bentzen","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.canrad.2024.07.004_bib0085","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S1470-2045(08)70077-9","article-title":"The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial","volume":"9","author":"Bentzen","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2024.07.004_bib0090","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.1200\/JCO.20.01363","article-title":"Hypofractionated versus standard fractionated radiotherapy in patients with early breast cancer or ductal carcinoma in situ in a randomized phase III Trial: the DBCG HYPO trial","volume":"38","author":"Offersen","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2024.07.004_bib0095","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1016\/S0140-6736(20)30932-6","article-title":"Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial","volume":"395","author":"Brunt","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.canrad.2024.07.004_bib0100","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0140-6736(22)01246-6","article-title":"Radiation doses and fractionation schedules in non-low-risk ductal carcinoma in situ in the breast (BIG 3-07\/TROG 07.01): a randomised, factorial, multicentre, open-label, phase 3 study","volume":"400","author":"Chua","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.canrad.2024.07.004_bib0105","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.ijrobp.2022.07.2320","article-title":"NRG RTOG 1005: a phase III trial of hypofractionated whole breast irradiation with concurrent boost vs. conventional whole breast irradiation plus sequential boost following lumpectomy for high risk early-stage breast cancer","volume":"114","author":"Vicini","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2024.07.004_bib0110","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1016\/j.ijrobp.2023.08.029","article-title":"Patient-reported and toxicity results from the FABREC study: a multicenter randomized trial of hypofractionated vs. conventionally-fractionated postmastectomy radiation therapy after implant-based reconstruction","volume":"117","author":"Wong","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2024.07.004_bib0115","doi-asserted-by":"crossref","first-page":"S76","DOI":"10.1016\/S0167-8140(22)02478-1","article-title":"OC-0102 DBCG phase III randomized trial of hypo- vs. standard fractionated RT in 2879 pN+ breast cancer pts","volume":"170","author":"Offersen","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2024.07.004_bib0120","doi-asserted-by":"crossref","first-page":"S625","DOI":"10.1016\/S0167-8140(23)08699-1","article-title":"OC-0758 HypoG-01: UNICANCER phase 3 trial of locoregional hypo vs. normo fractionated RT in early breast cancer","volume":"182","author":"Rivera","year":"2023","journal-title":"Radiother Oncol"}],"container-title":["Cancer\/Radioth\u00e9rapie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321824001306?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321824001306?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T16:18:36Z","timestamp":1730391516000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1278321824001306"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":12,"journal-issue":{"issue":"6-7","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S1278321824001306"],"URL":"https:\/\/doi.org\/10.1016\/j.canrad.2024.07.004","relation":{},"ISSN":["1278-3218"],"issn-type":[{"type":"print","value":"1278-3218"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Practice-changing trials on breast cancer","name":"articletitle","label":"Article Title"},{"value":"Cancer\/Radioth\u00e9rapie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canrad.2024.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Soci\u00e9t\u00e9 fran\u00e7aise de radioth\u00e9rapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}